IMNP Insider Trading Activity and SEC Form 4 Filings
IMNP insider trading summary
No open-market insider purchases or sales of Immune Pharmaceuticals Inc (IMNP) have been reported on SEC Form 4 in the past 12 months.
Latest IMNP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 22, 2018 | Anthony S. Fiorino | Chief Medical Officer and COO | Buy | $6K (25,000 @ $0.24) |
| May 17, 2018 | Anthony S. Fiorino | Chief Medical Officer and COO | Buy | $13K (50,000 @ $0.26) |
| Jan 4, 2017 | Daniel Kazado | Director | Buy | $14K (76,503 @ $0.19) |
| Dec 16, 2016 | Daniel Kazado | Director | Buy | $30K (161,377 @ $0.19) |
| Aug 4, 2016 | Daniel Gedeon Teper | CEO | Buy | $356K (937,500 @ $0.38) |
| Aug 4, 2016 | Monica E. Luchi | EVP & CMO | Buy | $350K (777,778 @ $0.45) |
| Aug 4, 2016 | Daniel Kazado | Director | Buy | $300K (666,667 @ $0.45) |
| Jan 26, 2016 | Daniel Gedeon Teper | CEO | Buy | $25K (42,000 @ $0.59) |
| Jan 19, 2016 | Daniel Gedeon Teper | CEO | Buy | $25K (44,200 @ $0.57) |
| Jan 12, 2016 | Daniel Gedeon Teper | CEO | Buy | $25K (39,400 @ $0.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.